SBIR Inside Track: SBA Releases Proposed SBIR & STTR Regulations Open for Public Comment Until July 16, 2012
Are you interested in shaping the future of one of the largest sources of early stage technology funding and support? As a stakeholder in the cancer research and technology development community, the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Development Center invites you to take advantage of an opportunity to comment on the revised guidance that will impact the eligibility and governance of the SBIR & STTR Programs.
As you may know, the programs were recently reauthorized by Congress and signed into law by President Obama at the end of 2011. The Small Business Administration (SBA) has now released proposed rules on the revised regulations governing the size and eligibility of SBIR & STTR participants, and is soliciting feedback from small businesses, investors and other stakeholders as part of a public comment period in the Federal Register and at regulations.gov.
This proposed rule would implement provisions of the SBIR/STTR Reauthorization Act of 2011. The rules address ownership, control, and affiliation issues for participants in the SBIR & STTR programs, including participants that are majority-owned by multiple venture capital operating companies, private equity firms, or hedge funds.
This is your opportunity to share your perspective on how the program can most effectively stimulate important technology innovations in our nation. Please take the time to weigh in. To submit a formal public comment, please visit the Federal Register or regulations.gov. Your feedback is critical to ensuring that the new changes made are practical, sensible, and acceptable to the business communities and government entities served by the SBIR & STTR Programs. We appreciate and value your input!
For more information, or if you have any questions about the NCI SBIR Program, please contact the NCI SBIR Development Center at: email@example.com.
The SBIR & STTR Programs are set-aside programs in agencies across the federal government for domestic small businesses to engage in research and development that has the potential or commercialization and public benefit. These programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer.